Results 11 to 20 of about 5,801 (166)
Why Molnupiravir Fails in Hospitalized Patients
mBio, 2022 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life.
Ashley N. Brown +6 more
doaj +3 more sources
Frontiers in Veterinary ScienceAlthough not registered for feline infectious peritonitis (FIP) in Japan, nucleoside analogs have shown efficacy and we have been offering them to owners of cats with FIP at our clinic since January 2020. The aim of this study was to investigate outcomes
Okihiro Sase +3 more
exaly +3 more sources
Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population. [PDF]
Med J AustABSTRACT Antivirals for mild‐to‐moderate coronavirus disease 2019 (COVID‐19) were adopted for use based on trials in unvaccinated adults during the pre‐Omicron period. In today's broadly immune populations, where the risk of hospitalisation and death has decreased substantially, there is a lack of high‐quality contemporary evidence to support routine ...
Mudrik-Zohar H +7 more
europepmc +2 more sources
Computational Analysis of Molnupiravir [PDF]
International Journal of Molecular Sciences, 2022 In this work, we report in-depth computational studies of three plausible tautomeric forms, generated through the migration of two acidic protons of the N4-hydroxylcytosine fragment, of molnupiravir, which is emerging as an efficient drug to treat COVID-19. The DFT calculations were performed to verify the structure of these tautomers, as well as their
Artem Sharov +4 more
openaire +3 more sources
Molnupiravir: coding for catastrophe [PDF]
Nature Structural & Molecular Biology, 2021 Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication
Brandon, Malone, Elizabeth A, Campbell
openaire +2 more sources
Качественная клиническая практика, 2022 Molnupiravir is an antiviral drug with a broad spectrum of activity against RNA viruses. The safety of molnupiravir in clinical trials with COVID-19 was analyzed.
A. L. Khokhlov, J. V. Rybachkova
doaj +1 more source
Interaction between warfarin and molnupiravir in a patient with coronavirus disease 2019 infection
Journal of Family Medicine and Primary Care, 2022 Molnupiravir is a novel antiviral agent for coronavirus disease 2019 (COVID-19) treatment. Warfarin is an oral anticoagulation agent with difficult management due to drug interactions.
Hikari Mizutani +3 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant.Objective ...
Rongrong Zou +15 more
doaj +1 more source
Molnupiravir for treating COVID-19 [PDF]
Cochrane Database of Systematic Reviews, 2022 Objectives\ud This is a protocol for a Cochrane Review (intervention). The objectives are as follows:\ud \ud To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.
Ochodo, Eleanor +7 more
openaire +1 more source
Infectious Diseases and Therapy, 2023 Introduction Molnupiravir is an oral antiviral drug that received special approval for emergency use in Japan on December 24 2021 for infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Masahiro Kimata +4 more
doaj +1 more source